Back to search results
NCT06596616

Gadopiclenol vs Gadoxetate MRI for Liver Lesions

Enrolling by Invitation
Not specifiedAges 18–89Observational
Icahn School of Medicine at Mount Sinai
~23 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:RadiologyGadopiclenol

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Lesion Detection
Measured over End of study, at 6 months

Conditions

Liver Lesion

Explore related trials

Chronic Liver DiseaseLiver Lesion

NCT06596616

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • BMEII

    New York, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sara Lewis, MD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Acute renal insufficiency.
Severe chronic renal insufficiency (GFR \<30 mL/min/1.73 m2).
Age \<18y.
Unable or unwilling to give informed consent.
Contraindications for MRI (such as pacemakers, infusion pumps, pregnancy, allergy or previous adverse reactions to gadolinium contrast agents, severe claustrophobia).

What this trial measures

  • Lesion DetectionEnd of study, at 6 months

    Lesion detection (for any enhancing lesions including benign and malignant lesions, excluding cysts and completely necrotic treated malignant lesions) will be evaluated both for gadopiclenol-enhanced study (including unenhanced sequences from index MRI) and gadoxetate-enhanced MRI (the reference standard method): will be classified for each post- contrast phase as 0: no visible enhancing lesion, 1: visible enhancing lesion.